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Abstract
Background: The pathomechanisms underlying aortic valve degeneration are incompletely 
understood. Therefore, the aim of our work was to assess the quantitative changes of proli-
feration and apoptosis accompanied by cellular phenotype alternations and matrix secretion 
in aortic sclerotic and stenotic valves and degenerative bioprostheses, as well as to detect the 
expression pattern of the rapamycin receptor FKBP12 across these three valve types.
Methods: Mild-to-moderate sclerotic and stenotic valves and degenerative bioprostheses from 
30 patients (n = 10 per group) were collected at autopsy or by surgery. Ki67+, FKBP12+,  
alpha-actin+, HSP47+ and TUNEL+ apoptotic cells were analyzed by immunohistochemistry.
Results: The main finding was the reduced proliferation and increased apoptosis in stenotic 
valves (ST) compared to the sclerotic ones (SC) (proliferation: ST: 20.8 ± 2.0% vs. SC: 30.1 ± 
± 2.2%, apoptosis: ST: 40.7 ± 5.0% vs. SC: 28.0 ± 5.1%, p < 0.05, respectively). Analogical 
alternations were found in degenerative bioprostheses (BP) (proliferation: 4.8 ± 2.3%; apop-
tosis: 13.1 ± 6.8%). Corresponding changes were observed in the valve cellularity (ST: 893 ±  
± 168, SC: 1034 ± 284, BP: 385 ± 179 cells/mm2, p < 0.05, respectively). The FKBP12 
signaling was reduced in diseased valves and bioprostheses (ST: 28.1 ± 3.6%, SC: 42.2 ±  
± 3.8%, BP: 5.8 ± 1.9%, p < 0.05, respectively). Further, the augmented alpha-actin expression 
was observed as the degenerative process progressed (ST: 30.3 ± 5.0%, SC: 22.6 ± 2.7%, BP:  
8.7 ± 4.0%, p < 0.05, respectively), followed by the upregulation of HSP47 (ST: 22.6 ± 2.8%, 
SC: 15.4 ± 2.1%, BP: 3.4 ± 1.0%, p < 0.05, respectively) and consecutive matrix accumulation.
Conclusions: The imbalance between proliferation and apoptosis with cellular phenotypical 
shift and subsequent matrix secretion may contribute to aortic valve stenosis and bioprosthesis 
degeneration. The identification of FKBP12 expression may implicate potential therapeutic 
strategies. (Cardiol J 2013; 20, 3: 268–275)
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Introduction
Degenerative aortic valve stenosis is a very 
common cardiovascular disorder worldwide [1]. 
Despite significant advances in diagnosis and 
management, pathological processes underlying 
stenotic valve disease are still poorly understood 
[2]. Previous studies have identified several unique 
pathomechanisms that are believed to contribute 
to the progression of the aortic valve degenera-
tion. Herein, the most important ones comprise 
apoptotic body formation with subsequent calci-
fication, acquirement of the smooth muscle cell 
typical marker alpha-actin by valvular interstitial 
cells (VICs) and matrix disarrangement [3]. Aortic 
valve degeneration seems to be an active process 
involving both enhanced cell proliferation and 
apoptosis [4]. However, the extent and the time-
-dependent onset of these two processes have not 
been precisely explored yet. 
Incomplete knowledge about the valve patho-
logy impinges adequate treatment. Nowadays, 
valve replacement remains the only effective the-
rapy [2]. Unfortunately, despite improvements in 
heart valve tissue engineering [5], a relatively fast 
bioprosthesis (BP) degeneration is a limitation to 
this method. That is why the understanding of the 
degeneration pattern of bioprostheses, particularly 
in comparison with the progress of native valve 
disease, could account for the development of new 
technologies supporting prolonged durability of 
valve substitutes. As an alternative to the invasive 
valve treatment, drug-based experimental therapy 
concepts such as the application of statins [6], 
blocking of Rho pathway [7] or TGF-beta1 signaling 
[8] have introduced a new promising therapeutic 
field. Since aortic valve lesions resemble arterial 
atherosclerotic plaques [9], potent antirestenotic 
drug — rapamycin — could represent another 
possible option to treat valve disease. 
Against this background, the aim of our pre-
sent study was to evaluate the histological cha-
racteristics involving the spatiotemporal pattern 
of proliferation, apoptosis and VIC activation by 
comparing mild-to-moderate, stenotic aortic valves 
and degenerative BP, as well as to detect FKBP12 
receptors for rapamycin in these 3 valve types. 
Methods
Patients and valve specimens
In the frame of a  prospective study valve 
probes from a total of 30 patients were removed 
either during surgical valve replacement (10 native 
end-stage stenotic aortic valves, 10 degenera-
tive porcine aortic bioprostheses) or at autopsy 
(10 mild-to-moderate aortic sclerotic valves). The 
diagnosis of aortic valve stenosis was made on 
the basis of a comprehensive anamnesis, physical 
examination, echocardiographic and invasive find-
ings. Exclusion criteria comprised the presence of 
rheumatic disease, endocarditis, bicuspid valves 
and other coexisting valvular dysfunctions. The 
severity of valve calcification in stenotic aortic 
valves was graded semiquantitatively by echo-
cardiography [10]. All of these valves showed 
moderate to severe calcification. Mild-to-moderate 
sclerotic aortic valves meeting the following mac-
roscopic criteria: opaque leaflets with focal areas 
of mild thickening and increased stiffness, but no 
significant outflow obstruction and no relevant 
calcification [11] served as controls. There was 
no documented history of a clinically significant 
aortic valve stenosis among patients with mild-
to-moderate diseased valves. In order to compare 
the course of degeneration process in native valves 
to that in porcine bioprostheses, 7 Carpentier- 
-Edwards and 3 Hancock/Hancock II devices with 
a mean duration of implant of 14 ± 4 years were 
explanted because of their degeneration-associated 
malfunction. The exact patients’ characteristics are 
demonstrated in Table 1. Informed consent for the 
valve exploration was provided by each patient. 
The study was approved by the local ethics com-
mittee and conforms to the principles outlined in 
the Declaration of Helsinki.
Immunohistochemistry
The immunohistochemical examinations were 
conducted according to our previous protocols 
[12–14]. Specifically, valvular specimens were fixed 
in 4.5% buffered formaldehyde and embedded in 
paraffin. Serial sections (4 µm) were taken verti-
cally through the diseased cusp and sinus near the 
centre of the leaflet adjacent to calcified areas for 
immunohistochemical analysis. The specimens 
were not decalcified before sectioning to optimize 
antigen preservation. After preparation in xylol 
and alcohol, specimens underwent proteolysis with 
either 3% citrate (pH 6.0) or target unmasking 
fluid (PanPath Inc., Amsterdam, the Netherlands). 
Non-specific antibody binding sites were blocked 
by fetal calf serum (FCS, dilution for FKBP12, 
alpha-actin and HSP47: 1:25) or rabbit serum 
(dilution for Ki67: 1:20) for 30 min. Thereafter, the 
specific antibodies either of monoclonal (anti-Ki67: 
1:2, clone MIB-1, Dako, Hamburg, Germany; 
anti-alpha-actin: 1:300, clone 1A4, Sigma, Dies-
senhofen, Germany; anti-HSP47: 1:1000, clone 
M16.10A1, Calbiochem, Schwalbach, Germany) 
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or polyclonal (anti-FKBP12: 1:500, Biomol, Ham-
burg, Germany) origin were used. For polyclonal 
antibodies, AffiniPure mouse anti-rabbit IgG (Dia-
nova) was additionally applied for 30 min at room 
temperature following primary antibody incubation. 
The visualization of antibody-protein complexes 
was performed by means of the APAAP technique 
(Alkaline Phosphatase Anti-Alkaline Phosphatase; 
Boehringer, Mannheim, Germany) with Fast Red 
(4-Chloro-2-Methylbenzendiazonium/3-Hydroxy-2-
-Naphthoesäure2,4-Dimethylanilid Phospat; Sigma, 
Diessenhofen, Germany) as a chromogenic substra-
te. The nuclei were counterstained with hematoxy-
lin (Merck, Darmstadt, Germany). Negative controls 
consisted in omitting of the specific antibodies.
In situ cell death detection (TUNEL-Assay: 
TdT-Mediated dUTP Nick End Labeling)
The immunohistochemical identification of 
apoptotic cells was performed in terms of labeling 
of DNA strand breaks with modified nucleotides. 
In detail, following the application of proteinase K 
(1:1000, 30 min at 37°C) the unspecific antibody 
sites were blocked with FCS (1:25, 30 min at 
20°C). Subsequently, the terminal deoxynucleotidyl 
transferase (TdT, Boehringer, Mannheim, Ger-
many) was used as a catalyst of polymerization of 
fluorescein labeled nucleotides (Boehringer, Man-
nheim, Germany) to free 3’-OH DNA ends. Then, 
the fluorescein labeled nucleotides were detected 
by anti-fluorescein antibody Fab fragments from 
sheep (Boehringer, Mannheim, Germany) conju-
gated with alcaline phosphatase (30 min, 37°C). 
Eventually, a colour reaction was conducted with 
Fast Red (Sigma, Diessenhofen, Germany). Nuclei 
were stained with hematoxylin. In each experiment 
2 negative controls were carried out with labeled 
nucleotides without incubation with TdT.
Histology
Photomicrographs were obtained by an Opti-
phot-2 microscope (Nikon, Düsseldorf, Germany) 
and a downstream KP-C 553 CCD video camera 
(Hitachi, Rodgau, Germany) [11–13]. A computer-
-assisted morphometric system (VFG 1 graphic 
card/VIBAM 0.0 software) was used to calculate 
cell density and expression of the determined 
markers. Five randomly selected areas (0.04 mm2 
each) were explored in each valve layer: ven-
tricularis, spongiosa, fibrosa. The percentage of 
immunolabeled cells was assessed as a number 
of stained cells per total cell number within each 
layer. Morphometric analysis was performed by 
2 independent examiners.
In order to distinguish valve layers from each 
other Azan trichome staining for collagen fibres 
and van Gieson elastica staining for elastic fibres 
were conducted.
Table 1. Characteristics of the patients’ cohort. 
SC (n = 10) ST (n = 10) BP (n = 10) P
Age [years] 61.4 ± 12.5 70.2 ± 9.0 65.5 ± 8.7 0.174
Male gender 3 (30%) 8 (80%) 6 (60%) 0.076
Coronary artery disease 3 (30%) 7 (70%) 4 (40%) 0.175
Peripheral artery occlusive disease 0 (0%) 1 (10%) 1 (10%) 0.585
Cardiovascular risk factors
Arterial hypertension 3 (30%) 8 (80%) 7 (70%) 0.054
Diabetes mellitus 2 (20%) 5 (50%) 1 (10%) 0.109
Hyperlipidemia 1 (10%) 5 (50%) 5 (50%) 0.101
Smoker 1 (10%) 4 (40%) 3 (30%) 0.303
Obesity 1 (10%) 1 (10%) 4 (40%) 0.153
Familial disposition 0 (0%) 3 (30%) 1 (10%) 0.133
Medication
Aspirin 4 (40%) 7 (70%) 6 (60%) 0.387
ACE inhibitor 3 (30%) 6 (60%) 7 (70%) 0.175
Beta-blocker 4 (40%) 8 (80%) 6 (60%) 0.189
Statin 3 (30%) 7 (70%) 4 (40%) 0.175
Values are presented as a mean ± SD. Values in brackets conform to percentages; SC — mild-to-moderate aortic sclerosis; ST — end- 
-stage aortic stenosis; BP — degenerative aortic bioprosthesis; ACE — angiotensin-converting enzyme; P — probability value
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Statistical analysis
Statistical analysis was performed by SPSS 
Inc. (version 19.0). All parameters were presented 
as a mean value ± standard derivation. In order to 
assess possible differences in marker expression 
levels between 3 groups of valves, the 1-way ANOVA 
test with the post-hoc Tukey-B analysis was used. 
Categorical variables were compared across the 
groups by means of the c2 test. P value of under 
0.05 was considered to be statistically significant. 
Two-tailed bivariate correlations were determined 
by the Pearson’s coefficient. 
Results
The main finding of our study was the decrea-
sing proliferation rate and the increasing apoptotic 
index in the time course of the degeneration process 
of the native human aortic valves (Figs. 1A–D). 
About one third of all VICs were proliferating in 
the mild-to-moderate sclerotic valves, as indicated 
by Ki67+ cells (SC: 30.1 ± 2.2%, Figs. 1A, 2). The 
number of mitotic cells reduced in stenotic valves 
(ST: 20.8 ± 2.0%, Figs. 1B, 2). On the contrary, 
apoptotic activity, expressed by a percentage of 
TUNEL+ cells, was detected in 28.0 ± 5.1% of 
VICs in sclerotic valves and increased as degenera-
tion process proceeded (ST: 40.7 ± 5.0%, Figs. 1C, 
D, 2). In consequence, the apoptosis/proliferation 
ratio amounted to about 1 in only mild-to-moderate 
altered valves, whereas it increased to approxima-
tely 2 at the end stage of valve disease. Similarly, 
the apoptosis outnumbered the proliferation rate 
in bioprostheses by about 2 times (BP: apoptosis: 
13.1 ± 6.8%, proliferation: 4.8 ± 2.3%, Figs. 1E, F, 2). 
The above differences in proliferation and apoptosis 
Figure 1. Photomicrographs demonstrating a  decreasing number of Ki67+ proliferating cells (A. Sclerotic valve; 
B. Stenotic valve) and an increasing TUNEL+ apoptotic activity (C. Sclerotic valve; D. Stenotic valve) in a time course 
of the degeneration process of a native aortic valve. Analogically, the prevalence of apoptosis (F) over proliferation (E) 
in a porcine degenerative bioprosthesis; F — fibrosa; S — spongiosa; V — ventricularis; Bar = 30 µm.
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were significant across the 3 valve types (p < 0.05, 
respectively). A comparison of the corresponding 
changes in proliferation and apoptosis revealed 
a strong positive correlation between these 2 pro-
cesses in sclerotic valves (r = 0.7, p = 0.02) and 
a strong negative correlation in the stenotic ones 
(r = –0.7, p = 0.02). The described interplay 
between proliferation and apoptosis resulted in 
changes in the valve cellularity (SC: 1034 ± 284 
cells/mm2, ST: 893 ± 168 cells/mm2, BP: 385 ± 
± 179 cells/mm2, p < 0.05).
Parallel to the enhanced cell turnover, we 
observed the upregulation of the signaling for 
FKBP12, the receptor for rapamycin, in sclerotic 
valves (SC: 42.2 ± 3.8%) which declined signi-
ficantly in the stenotic ones (ST: 28.1 ± 3.6%, 
Figs. 3A, B, 4). In the bioprostheses the FKBP12 
immunolabeling was detected in 5.8 ± 1.9% of 
cells (p < 0.05 between 3 valve types, Figs. 3C, 4). 
Interestingly, the FKBP12 signals predominated 
in the fibrosa of both valve types and at the aortic 
site of the bioprostheses (p < 0.05 compared to the 
remaining layers, respectively, Figs. 3, 4). 
Moreover, we identified the relevant part of 
VICs to be positive for alpha-actin marker in all 































Figure 2. A graphic chart representing a percentual 
relationship between proliferation (Ki67) and apop-
tosis (TUNEL) in valvular interstitial cells (VICs) of 
sclerotic (SC) and stenotic valves (ST) as well as 
bioprostheses (BP).
Figure 3. Declining FKBP12 signal density in a  native stenotic aortic valve (B) compared to a  sclerotic one (A). 
C. Distinct FKBP12 immunolabeling in a bioprosthesis. Remarkably, fibrosa is a predilection site for FKBP12 signaling 
in all 3 valve types. Arrows indicate FKBP12+ cells adjacent to a microvessel in a border zone between fibrosa and 
























Figure 4. Percentual fraction of FKBP12 positive cells 
among valvular interstitial cells (VICs) in 3 valve layers: 
ventricularis, spongiosa, fibrosa across 3 types of valves; 
SC — sclerotic valves; ST — stenotic valves; BP — bio-
prostheses.
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30.3 ± 5.0%, BP: 8.7 ± 4.0%, p < 0.05). These 
myofibroblast-like alpha-actin+ cells were mostly 
located in the ventricularis of the sclerotic and 
stenotic valves (alpha-actin ratio in ventricularis: 
spongiosa: fibrosa for SC: 2.2: 1.0: 1.8, p < 0.001; 
for ST: 2.5: 1.0: 1.8, p < 0.001), whereas in the 
bioprostheses the layers close to aorta were the 
predilection sites for this cell type (BP: 1.0: 3.4: 
9.1, respectively, p < 0.001, Figs. 5, 6).
Along with the increase in the alpha-actin 
expression, the upregulation of a collagen-specific 
molecular chaperon HSP47, particularly in the 
fibrosa of the valves (SC: 15.4 ± 2.1%, ST: 22.6 ± 
Figure 5. Percentual fraction of alpha-actin positive cells 
among valvular interstitial cells (VICs) in 3 valve lay-
ers: ventricularis, spongiosa, fibrosa across 3 types of; 

























± 2.8%, BP: 3.4 ± 1.0%, p < 0.05) with consecu-
tive matrix accumulation, was detected.
Discussion
Our present study has provided new insights 
into the degenerative process of native human 
aortic valves with emphasis on the cell turnover 
in time course, potential differences in the disease 
progression between native valves and biopros-
theses and possible therapeutic strategies. Par-
ticularly, we have demonstrated that in the initial 
stage of the degenerative process the proliferation 
rate of about 30% of all interstitial valve cells was 
well balanced by apoptosis. This indicates that, 
in comparison with healthy aortic valves which 
are characterized by very low proliferation and 
apoptosis indexes [15], the cell turnover rate 
increases rapidly in the early phase of the valve 
disease, similarly as during fetal development [15]. 
Likewise, enhanced cell proliferation was observed 
in pediatric and adult diseased aortic valves [4]. 
Our data show that with time in stenotic 
aortic valves proliferation decreased and apop-
tosis increased with apoptosis/proliferation ratio 
of approximately 2, analogically to that found in 
bioprostheses. In mild-to-moderate degenerative 
valves the correlation between proliferation and 
apoptosis was significantly positive. In contrast, 
it was strongly negative in the stenotic valves. It 
seems that at the beginning of the degenerative 
process the proliferation and apoptosis as 2 coun-
teracting processes balance each other. However, 
it is not known whether the cell apoptosis occurs at 
first as a reaction to the undefined trauma followed 
by the attempt of rebalance due to the activation 
of proliferation or on the contrary, apoptosis is 
secondary to the cell proliferation which takes 
Figure 6. Predominance of alpha-actin signals in a ventricularis of a sclerotic valve (A) and of a stenotic valve (B). In 
contrast, alpha-actin+ cells are almost exclusively found in a fibrosa of a bioprosthesis (C); F — fibrosa; S — spon-
giosa; V — ventricularis; Bar = 30 µm.
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place in order to reproduce cell population capable 
of renewing of the damaged extracellular matrix. 
In stenotic aortic valves the negative correlation 
between apoptosis and proliferation points to the 
dysregulation in cell turnover and subsequently to 
the irreversible disturbance of a valve homeostasis. 
Increased apoptosis seems to be associated with 
augmented calcification [3]. One may assume that 
whereas the mild-to-moderate stage of degenerati-
ve valve disease with in fact pathologically augmen-
ted cell activation but still sustained cell balance is 
potentially reversible, the stenotic valve with the 
predominance of apoptosis represents a “point of 
no return” in the time course of the degeneration 
process. The diagnosis based on evaluation of such 
indicator of valve disease progression could be of 
a great importance for identification of patients 
with not yet advanced disease who could profit 
from early treatment other than surgical valve re-
placement. Likewise, Wirrig et al. [4] proposed the 
expression of osteogenic differentiation molecules 
to be a crucial marker indicating a transition from 
a non-calcified state to the late stage of a calcified 
aortic valve disease. 
Another finding of our study was the detection 
of FKBP12 signaling in diseased valves, which 
could implicate potential therapeutic strategies. 
The exact role of FKBP12 in the pathophysio-
logy of cardiovascular system is not known [16]. 
As a  receptor for rapamycin FKBP12 regulates 
various processes connected with cell growth, 
proliferation and protein synthesis [17]. In analogy 
to the prevention of vessel restenosis, the use of 
rapamycin could be of a  therapeutic relevance. 
The rapamycin-associated antiproliferative actions 
[18] might cease the exaggerated reaction of mu-
tual intensification of proliferation and apoptosis. 
Keeping in mind the spatiotemporal pattern of 
FKBP12 receptor and the apoptosis/proliferation 
ratios, rapamycin application should be restricted 
to the early stage of degenerative valve process at 
the fibrosa site. Moreover, the anti-inflammatory 
properties of rapamycin could attenuate the inflam-
mation contributing to the valve disease [14]. 
In our study, besides the unbalance between 
proliferation and apoptosis, the upregulation of 
alpha-actin+ cells was related to the degeneration 
process. Interestingly, the majority of alpha-actin 
signals were found in the ventricularis of the 
diseased native valves. In contrast, alpha-actin 
immunolabeling was almost only detected in the 
fibrosa of bioprostheses. This fact suggests dif-
ferent origins of alpha-actin+ cells and/or their 
precursors in the diseased native valves and bio-
prostheses. Specifically, alpha-actin+ cells could 
migrate from neighboring cardiac tissue into ven-
tricularis of native valves through the reactivation 
of embryonic development pathways consisting in 
population of valve leaflets with endocardial cells 
that have undergone an epithelial-to-mesenchymal 
transformation [19]. In contrast, the localization of 
alpha-actin markers in the fibrosa of bioprostheses 
indicates extra-cardiac source of these cells such as 
peripheral blood [12, 14] or aorta. It is also possible 
that different predilection sites for alpha-actin+ 
cells in impaired native valves and bioprotheses 
are a consequence of a valve type specific distri-
bution of factors promoting phenotypical shift from 
quiescent fibroblast-like cells which are typical for 
healthy valves [20] into myofibroblast-like cells. 
Either way, different parts of valves seem to accom-
plish an unequal contribution to the degeneration 
process dependent on the native or bioprosthetic 
valve type. 
Our work is limited to the investigations of 
the valve changes at certain time points without 
assessment of the progression from sclerotic to 
the end-stage stenotic valve disease. Moreover, 
the number of specimens examined was relatively 
small. Eventually, the study design comprised only 
morphological and immunohistochemical analysis. 
Nevertheless, the present work suggests some 
interesting valve degeneration pathomechanisms 
which should be further evaluated in larger studies 
with emphasis on the functional aspects under the 
application of molecular biological methods. 
Conclusions
Our study shows an imbalance between proli-
feration and apoptosis accompanied by the alpha-
-actin upregulation and matrix secretion in degene-
rative valves and bioprostheses. Identification and 
determination of FKBP12 spatiotemporal distri-
bution implicate its role in the valve degeneration 
process and provide a platform for new therapeutic 
strategies. The differences in the alpha-actin ex-
pression suggest different degeneration patterns 
in native valves and bioprostheses.
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